Suppr超能文献

慢性肾脏病中的心血管合并症:当前认知与未来研究需求

Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.

作者信息

Alani Hudaifa, Tamimi Asad, Tamimi Nihad

机构信息

Hudaifa Alani, Broomfield Hospital, Mid Essex NHS Trust, CM1 7ET Chelmsford, United Kingdom.

出版信息

World J Nephrol. 2014 Nov 6;3(4):156-68. doi: 10.5527/wjn.v3.i4.156.

Abstract

Chronic kidney disease (CKD) is recognised as a health concern globally and leads to high rates of morbidity, mortality and healthcare expenditure. CKD is itself an independent risk factor for unfavorable health outcomes that include cardiovascular disease (CVD). Coronary artery disease is the primary type of CVD in CKD patients and a significant cause of death among renal transplant patients. Traditional and non-traditional risk factors for CVD exist in patients with CKD. Traditional factors include smoking, hypertension, dyslipidemia and diabetes which are highly prevalent in CKD patients. Non-traditional risk factors of CKD are mainly uraemia-specific and increase in prevalence as kidney function declines. Some examples of uraemia-specific risk factors that have been well documented include low levels of haemoglobin, albuminuria, and abnormal bone and mineral metabolism. Therapeutic interventions targeted at more traditional risk factors which contribute to CVD, have not had the desired effect on lowering CVD events and mortality in those suffering with CKD. Future research is warranted to delineate clear evidence to the benefit of modifying non-traditional risk factors.

摘要

慢性肾脏病(CKD)被公认为是一个全球性的健康问题,会导致高发病率、高死亡率以及高额医疗支出。CKD本身就是导致不良健康结局的独立危险因素,这些不良结局包括心血管疾病(CVD)。冠状动脉疾病是CKD患者中CVD的主要类型,也是肾移植患者死亡的重要原因。CKD患者存在传统和非传统的CVD危险因素。传统因素包括吸烟、高血压、血脂异常和糖尿病,这些在CKD患者中非常普遍。CKD的非传统危险因素主要是尿毒症特异性的,并且随着肾功能下降患病率增加。一些有充分记录的尿毒症特异性危险因素的例子包括血红蛋白水平低、蛋白尿以及骨和矿物质代谢异常。针对导致CVD的更传统危险因素的治疗干预措施,对降低CKD患者的CVD事件和死亡率并未产生预期效果。有必要进行未来研究,以明确证明改变非传统危险因素的益处。

相似文献

1
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.
World J Nephrol. 2014 Nov 6;3(4):156-68. doi: 10.5527/wjn.v3.i4.156.
2
Cardiovascular disease and its relationship with chronic kidney disease.
Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2918-26.
3
Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.
Semin Dial. 2003 Mar-Apr;16(2):101-5. doi: 10.1046/j.1525-139x.2003.16025.x.
4
The link between chronic kidney disease and cardiovascular disease.
J Nephropathol. 2014 Jul;3(3):99-104. doi: 10.12860/jnp.2014.19. Epub 2014 Jul 1.
5
Chronic kidney disease and cardiovascular risk.
J Am Soc Hypertens. 2007 May-Jun;1(3):178-84. doi: 10.1016/j.jash.2007.01.010.
7
Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction.
Nephron Clin Pract. 2011;119(2):c171-7; discussion c177-8. doi: 10.1159/000325669. Epub 2011 Jul 28.
10
Arterial stiffness and increased cardiovascular risk in chronic kidney disease.
Int Urol Nephrol. 2015 Jul;47(7):1157-64. doi: 10.1007/s11255-015-1009-x. Epub 2015 May 20.

引用本文的文献

2
Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.
Ann Med Surg (Lond). 2024 Sep 25;86(11):6602-6618. doi: 10.1097/MS9.0000000000002592. eCollection 2024 Nov.
3
Key regulators of vascular calcification in chronic kidney disease: Hyperphosphatemia, BMP2, and RUNX2.
PeerJ. 2024 Sep 19;12:e18063. doi: 10.7717/peerj.18063. eCollection 2024.
4
Chinese herbal medicine may reduce major adverse cardiovascular events in patients with dialysis hypotension: A taiwan nationwide cohort study.
J Tradit Complement Med. 2024 Mar 6;14(5):550-557. doi: 10.1016/j.jtcme.2024.03.009. eCollection 2024 Sep.
6
Cardiovascular Morbidity in Systemic Lupus Erythematosus: A Single-Center Retrospective Study.
Cureus. 2024 Apr 8;16(4):e57842. doi: 10.7759/cureus.57842. eCollection 2024 Apr.
9
Resistin: A Potential Indicator of Aortic Stiffness in Non-Dialysis Chronic Kidney Disease Patients.
Medicina (Kaunas). 2023 Sep 13;59(9):1652. doi: 10.3390/medicina59091652.
10
Application of nanoparticles in the diagnosis and treatment of chronic kidney disease.
Front Med (Lausanne). 2023 Apr 17;10:1132355. doi: 10.3389/fmed.2023.1132355. eCollection 2023.

本文引用的文献

1
Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.
J Huazhong Univ Sci Technolog Med Sci. 2014 Aug;34(4):476-481. doi: 10.1007/s11596-014-1302-4. Epub 2014 Aug 19.
2
Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.
Int J Nephrol Renovasc Dis. 2014 May 8;7:161-8. doi: 10.2147/IJNRD.S41626. eCollection 2014.
3
Association between Serum Iron and the Severity of Coronary Artery Disease.
Int Cardiovasc Res J. 2013 Sep;7(3):95-8. Epub 2013 Sep 1.
4
Serum uric acid and chronic kidney disease: the role of hypertension.
PLoS One. 2013 Nov 12;8(11):e76827. doi: 10.1371/journal.pone.0076827. eCollection 2013.
5
Effect of allopurinol on blood pressure: a systematic review and meta-analysis.
J Clin Hypertens (Greenwich). 2013 Jun;15(6):435-42. doi: 10.1111/j.1751-7176.2012.00701.x. Epub 2012 Aug 20.
6
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease.
J Am Coll Cardiol. 2013 Mar 5;61(9):926-32. doi: 10.1016/j.jacc.2012.09.066.
9
Iron and vascular calcification. Is there a link?
Nephrol Dial Transplant. 2011 Apr;26(4):1137-45. doi: 10.1093/ndt/gfq858. Epub 2011 Feb 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验